Drugs Made In America Acquisition (DMAA) Competitors

$10.60 0.00 (0.00%)

Closing price 05/22/2026 03:46 PM Eastern

Extended Trading

$10.62 +0.02 (+0.14%)

As of 05/22/2026 04:30 PM Eastern

DMAA vs. ORC, PBT, LADR, TIGR, and CSR

Should you buy Drugs Made In America Acquisition stock or one of its competitors? MarketBeat compares Drugs Made In America Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Drugs Made In America Acquisition include Orchid Island Capital (ORC), Permian Basin Royalty Trust (PBT), Ladder Capital (LADR), UP Fintech (TIGR), and Centerspace (CSR). These companies are all part of the "trading" industry.

How does Drugs Made In America Acquisition compare to Orchid Island Capital?

Orchid Island Capital (NYSE:ORC) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

In the previous week, Orchid Island Capital's average media sentiment score of 0.00 equaled Drugs Made In America Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Orchid Island Capital	Neutral
Drugs Made In America Acquisition	Neutral

Orchid Island Capital has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

32.7% of Orchid Island Capital shares are owned by institutional investors. 0.4% of Orchid Island Capital shares are owned by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Orchid Island Capital currently has a consensus price target of $7.50, indicating a potential upside of 10.70%. Given Orchid Island Capital's stronger consensus rating and higher probable upside, analysts clearly believe Orchid Island Capital is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchid Island Capital	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Orchid Island Capital has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchid Island Capital	$414M	3.28	$159.03M	$0.75	9.03
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Orchid Island Capital's return on equity of 10.24% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchid Island Capital	N/A	10.24%	1.19%
Drugs Made In America Acquisition	N/A	N/A	N/A

Summary

Orchid Island Capital beats Drugs Made In America Acquisition on 7 of the 8 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Permian Basin Royalty Trust?

Permian Basin Royalty Trust (NYSE:PBT) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Permian Basin Royalty Trust has a net margin of 88.99% compared to Drugs Made In America Acquisition's net margin of 0.00%. Permian Basin Royalty Trust's return on equity of 9,061.81% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Permian Basin Royalty Trust	88.99%	9,061.81%	484.53%
Drugs Made In America Acquisition	N/A	N/A	N/A

28.9% of Permian Basin Royalty Trust shares are owned by institutional investors. 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Permian Basin Royalty Trust had 4 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 4 mentions for Permian Basin Royalty Trust and 0 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.00 beat Permian Basin Royalty Trust's score of -0.03 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Permian Basin Royalty Trust	Neutral
Drugs Made In America Acquisition	Neutral

Permian Basin Royalty Trust has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Permian Basin Royalty Trust	$16.13M	89.81	$14.30M	$0.32	97.12
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Permian Basin Royalty Trust	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Permian Basin Royalty Trust has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

Summary

Permian Basin Royalty Trust beats Drugs Made In America Acquisition on 8 of the 10 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Ladder Capital?

Ladder Capital (NYSE:LADR) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Ladder Capital presently has a consensus price target of $12.75, suggesting a potential upside of 26.05%. Given Ladder Capital's stronger consensus rating and higher possible upside, research analysts plainly believe Ladder Capital is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ladder Capital	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ladder Capital has a net margin of 13.82% compared to Drugs Made In America Acquisition's net margin of 0.00%. Ladder Capital's return on equity of 5.73% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ladder Capital	13.82%	5.73%	1.70%
Drugs Made In America Acquisition	N/A	N/A	N/A

In the previous week, Ladder Capital had 3 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 3 mentions for Ladder Capital and 0 mentions for Drugs Made In America Acquisition. Ladder Capital's average media sentiment score of 0.00 equaled Drugs Made In America Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Ladder Capital	Neutral
Drugs Made In America Acquisition	Neutral

62.3% of Ladder Capital shares are held by institutional investors. 12.0% of Ladder Capital shares are held by insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ladder Capital has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ladder Capital	$390.29M	3.30	$64.18M	$0.44	22.99
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Ladder Capital has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Summary

Ladder Capital beats Drugs Made In America Acquisition on 11 of the 11 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to UP Fintech?

Drugs Made In America Acquisition (NASDAQ:DMAA) and UP Fintech (NASDAQ:TIGR) are both small-cap trading companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

9.0% of UP Fintech shares are owned by institutional investors. 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Comparatively, 50.9% of UP Fintech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Drugs Made In America Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, UP Fintech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

UP Fintech has a consensus target price of $11.83, suggesting a potential upside of 171.39%. Given UP Fintech's stronger consensus rating and higher probable upside, analysts clearly believe UP Fintech is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
UP Fintech	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

UP Fintech has a net margin of 28.82% compared to Drugs Made In America Acquisition's net margin of 0.00%. UP Fintech's return on equity of 21.87% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Drugs Made In America Acquisition	N/A	N/A	N/A
UP Fintech	28.82%	21.87%	2.05%

In the previous week, UP Fintech had 14 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 14 mentions for UP Fintech and 0 mentions for Drugs Made In America Acquisition. UP Fintech's average media sentiment score of 0.45 beat Drugs Made In America Acquisition's score of 0.00 indicating that UP Fintech is being referred to more favorably in the news media.

Company	Overall Sentiment
Drugs Made In America Acquisition	Neutral
UP Fintech	Neutral

UP Fintech has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A
UP Fintech	$538.71M	1.54	$170.90M	$0.91	4.79

Summary

UP Fintech beats Drugs Made In America Acquisition on 12 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Centerspace?

Centerspace (NYSE:CSR) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Centerspace currently has a consensus price target of $69.40, indicating a potential upside of 1.92%. Given Centerspace's stronger consensus rating and higher probable upside, equities research analysts plainly believe Centerspace is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centerspace	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Centerspace has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centerspace	$273.66M	4.18	$17.59M	$0.45	151.31
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Centerspace had 2 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 2 mentions for Centerspace and 0 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.00 beat Centerspace's score of -0.10 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Centerspace	Neutral
Drugs Made In America Acquisition	Neutral

Centerspace has a net margin of 2.93% compared to Drugs Made In America Acquisition's net margin of 0.00%. Centerspace's return on equity of 0.94% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centerspace	2.93%	0.94%	0.40%
Drugs Made In America Acquisition	N/A	N/A	N/A

Centerspace has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

79.0% of Centerspace shares are owned by institutional investors. 0.5% of Centerspace shares are owned by insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Centerspace beats Drugs Made In America Acquisition on 10 of the 12 factors compared between the two stocks.

Get Drugs Made In America Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAA vs. The Competition

Export

Metric	Drugs Made In America Acquisition	Investment Offices Industry	Financial Sector	NASDAQ Exchange
Market Cap	$257.34M	$340.24M	$5.90B	$12.34B
Dividend Yield	N/A	N/A	5.21%	5.28%
P/E Ratio	N/A	0.71	15.90	25.66
Price / Sales	N/A	229.06	1,011.40	86.31
Price / Cash	N/A	135.71	92.81	56.67
Price / Book	N/A	262.59	6.60	7.14
Net Income	N/A	-$66.73M	$1.14B	$335.98M
7 Day Performance	0.14%	1.04%	1.05%	4.15%
1 Month Performance	0.47%	2.26%	2.04%	2.54%
1 Year Performance	N/A	6.88%	19.96%	35.06%

Drugs Made In America Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAA Drugs Made In America Acquisition	N/A	$10.60 flat	N/A	N/A	$257.34M	N/A	N/A	2	High Trading Volume
ORC Orchid Island Capital	1.7183 of 5 stars	$6.85 -1.1%	$7.50 +9.6%	-2.2%	$1.39B	$414M	9.13	2,018
PBT Permian Basin Royalty Trust	1.188 of 5 stars	$28.92 +5.9%	N/A	+177.2%	$1.35B	$16.13M	90.38	N/A	Gap Down
LADR Ladder Capital	4.8369 of 5 stars	$9.87 -1.4%	$12.75 +29.2%	-1.9%	$1.27B	$390.29M	22.42	60
TIGR UP Fintech	4.1615 of 5 stars	$6.16 -4.9%	$11.83 +92.1%	-50.2%	$1.23B	$538.71M	6.77	1,193	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Drugs Made In America Acquisition (DMAA) Competitors

DMAA vs. ORC, PBT, LADR, TIGR, and CSR

How does Drugs Made In America Acquisition compare to Orchid Island Capital?

Summary

How does Drugs Made In America Acquisition compare to Permian Basin Royalty Trust?

Summary

How does Drugs Made In America Acquisition compare to Ladder Capital?

Summary

How does Drugs Made In America Acquisition compare to UP Fintech?

Summary

How does Drugs Made In America Acquisition compare to Centerspace?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAA vs. The Competition

Drugs Made In America Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Drugs Made In America Acquisition (DMAA) Competitors

DMAA vs. ORC, PBT, LADR, TIGR, and CSR

How does Drugs Made In America Acquisition compare to Orchid Island Capital?

Does the media prefer ORC or DMAA?

Which has more volatility & risk, ORC or DMAA?

Do insiders and institutionals have more ownership in ORC or DMAA?

Do analysts prefer ORC or DMAA?

Which has stronger valuation & earnings, ORC or DMAA?

Is ORC or DMAA more profitable?

Summary

How does Drugs Made In America Acquisition compare to Permian Basin Royalty Trust?

Is PBT or DMAA more profitable?

Do insiders & institutionals have more ownership in PBT or DMAA?

Does the media prefer PBT or DMAA?

Which has higher earnings and valuation, PBT or DMAA?

Do analysts prefer PBT or DMAA?

Which has more volatility and risk, PBT or DMAA?

Summary

How does Drugs Made In America Acquisition compare to Ladder Capital?

Do analysts recommend LADR or DMAA?

Is LADR or DMAA more profitable?

Does the media favor LADR or DMAA?

Do institutionals and insiders have more ownership in LADR or DMAA?

Which has stronger valuation & earnings, LADR or DMAA?

Which has more risk and volatility, LADR or DMAA?

Summary

How does Drugs Made In America Acquisition compare to UP Fintech?

Do institutionals & insiders have more ownership in DMAA or TIGR?

Which has more volatility & risk, DMAA or TIGR?

Do analysts prefer DMAA or TIGR?

Is DMAA or TIGR more profitable?

Does the media refer more to DMAA or TIGR?

Which has higher valuation & earnings, DMAA or TIGR?

Summary

How does Drugs Made In America Acquisition compare to Centerspace?

Do analysts recommend CSR or DMAA?

Which has stronger valuation and earnings, CSR or DMAA?

Does the media prefer CSR or DMAA?

Is CSR or DMAA more profitable?

Which has more volatility & risk, CSR or DMAA?

Do institutionals and insiders believe in CSR or DMAA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAA vs. The Competition

Drugs Made In America Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools